Inhibiting de novo ceramide accumulation improves the systemic metabolic environment of C57Bl/6 mice with diet-induced obesity.
C57Bl/6 mice that consumed CON or HF chow for 3 months were treated concurrently with vehicle (V) or myriocin (M). Vascular
(aorta) (A) and liver (B) ceramide content, body mass (C), body composition (D), gonadal fat pad mass (E), area under the curve during a glucose tolerance test (GTT) (F) and insulin tolerance test (G). Fasting (6 h) serum triglycerides (H) and serum leptin (I) concentrations. Fasting (6 h) blood glucose (mg/dL) before the GTT in panel F was higher in HF-V (122 ± 8) vs. CON-V (95 ± 7) mice but was similar between HF-M (102 ± 5) and CON-M (96 ± 5) animals. *P < 0.05 CON vs. HF, #P < 0.05 M vs. V. Results represent mean ± SEM from 10 CON-V, 13 HF-V, 7 CON-M, and 13 HF-M mice. AU, arbitrary unit.